Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy
Abstract In the last months, conflicting evidence on a possible association between the use of semaglutide and incident nonarteritic anterior ischemic optic neuropathy (NAION) has emerged. A recently published study, which evaluated all patients with type 2 diabetes in Denmark, has shown with robust...
Saved in:
Main Authors: | Fernando K. Malerbi, Marcello C. Bertoluci |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | International Journal of Retina and Vitreous |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40942-024-00622-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes
by: Jakob Grauslund, et al.
Published: (2024-12-01) -
Investigating Elevated E-Selectin and P-Selectin Levels in Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patients: The Stepping Stone to a Future Clinical Approach
by: Syntia Nusanti, et al.
Published: (2024-10-01) -
Adverse effects of GLP – 1 Receptor Agonists
by: Anna Kasprzak, et al.
Published: (2025-02-01) -
Adalimumab-induced optic neuropathy in a patient with Behçet’s syndrome
by: Sofia Miranda, et al.
Published: (2025-01-01) -
Quantifying the spatial patterns of retinal ganglion cell loss and progression in optic neuropathy by applying a deep learning variational autoencoder approach to optical coherence tomography
by: Jui-Kai Wang, et al.
Published: (2025-02-01)